ArticleDiabetology & metabolic syndrome2014
Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study.
Article in Diabetology & metabolic syndrome, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Efficacy of DPP-4 Inhibitors on Seated and Ambulatory Blood Pressure in Type 2 Diabetes Mellitus.Diabetes, obesity & metabolism · 2026Pooled it
- Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.Cardiovascular diabetology · 2020Pooled it
- Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis.Lipids in health and disease · 2019Pooled it
- MicroRNAs modulated by DPP-4 inhibitor and bedtime NPH insulin therapy in individuals with type 2 diabetes.Frontiers in endocrinology · 2025Trial
- Liraglutide relieves cardiac dilated function than DPP-4 inhibitors.European journal of clinical investigation · 2018Trial
- Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.Cardiovascular diabetology · 2017Trial
- Diabetic cardiomyopathy: a comprehensive review of diagnosis, management, and future directions.Diabetology & metabolic syndrome · 2025Review
- Epicardial Adipose Tissue: A Potential Target to Improve Left Ventricular Diastolic Dysfunction.Reviews in cardiovascular medicine · 2025Review
- Relationship between saxagliptin use and left ventricular diastolic function assessed by cardiac MRI.Acta diabetologica · 2024Article
- Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up.Diagnostics (Basel, Switzerland) · 2023Article
- New antidiabetic therapy and HFpEF: light at the end of tunnel?Heart failure reviews · 2022Review
- Review
- Research status and trends of the diabetic cardiomyopathy in the past 10 years (2012-2021): A bibliometric analysis.Frontiers in cardiovascular medicine · 2022Article
- DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism.Heart and vessels · 2021Article
- Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?Journal of diabetes and its complications · 2020Review
- The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy.Frontiers in physiology · 2020Review
- Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments.Journal of echocardiography · 2019Review
- Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro.Acta pharmacologica Sinica · 2016Article
- Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.Heart and vessels · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlood glucose control is fundamental albeit not enough to prevent diabetic macrovascular complications. Dipeptidyl peptidase-4 (DPP-4) inhibitors are effective in improving metabolic parameters in patients with type 2 diabetes mellitus (T2DM) but little is known about its cardiovascular effects. We compared the DPP-4 inhibitor sitagliptin with bedtime NPH insulin (NPH) as add-on therapy in patients with T2DM, aiming to ascertain which drug would have additional cardioprotective effects.
methodsThirty-five T2DM patients inadequately controlled with metformin plus glyburide were randomized to receive sitagliptin (n = 18) or NPH (n = 17) for 24 weeks. Fasting plasma glucose, HbA1c, lipid profile, C-reactive protein, active glucagon-like peptide (aGLP-1) levels, 24-hour ambulatory blood pressure measurement and comprehensive 2-dimensional echocardiogram were determined before and after treatments.
resultsBoth sitagliptin and NPH therapies decreased HbA1c levels after 24 weeks. Fasting plasma glucose and triglyceride levels decreased in the NPH group whereas only sitagliptin increased aGLP-1 levels. Left ventricular diastolic dysfunction (LVDD) was detected in 58.6% of twenty-nine patients evaluated. Beneficial effects in LVDD were observed in 75% and 11% of patients treated with sitagliptin and NPH, respectively (p = 0.015). Neither therapy changed C-reactive protein or blood pressure.
conclusionsSitagliptin and bedtime NPH were similarly effective on glucose control. Improvement in LVDD in T2DM patients treated with sitagliptin was suggested, probably related to the increase of aGLP-1 levels. Therefore, DPP-4 inhibitor seems to have cardioprotective effects independent of glucose control and may have a role in the prevention of diabetic cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.